

A)
0
20
40
Minutes
INFE-HA-1-V1
B)
0
20
40
Minutes
INFE-HA-1-V2
C)
0
20
40
Minutes
INFE-HA-1-V3
D)
0
20
40
Minutes
INFE-HA-1-V4

FIG. 1



A)
0
20
40
Minutes
INF-HA-1-V1
B)
0
20
40
Minutes
INF-HA-1-V2
C)
0
20
40
Minutes
INF-HA-1-V3
D)
0
20
40
Minutes
INF-HA-1-V4

FIG. 2



A)
0
20
40
Minutes
INF-HA-2-V1
B)
0
20
40
Minutes
INF-HA-2-V2
C)
0
20
40
Minutes
INF-HA-2-V3
D)
0
20
40
Minutes
INF-HA-2-V4

FIG. 3





A)
B)
0
20
40
Minutes
0
20
40
Minutes
INF-HB-1-V1
INF-HB-1-V2
C)
D)
0
20
40
Minutes
0
20
40
Minutes
INF-HB-1-V3
INF-HB-1-V4

FIG. 4




INFE-HA-1-V1

FIG. 5A




INFE-HA-1-V2

FIG. 5B




INFE-HA-1-V3

FIG. 5C




INFE-HA-1-V4

FIG. 5D




INF-HA-1-V1

FIG. 6A




INF-HA-1-V2

FIG. 6B




INF-HA-1-V3

FIG. 6C




INF-HA-1-V4

FIG. 6D




INF-HA-2-V1

FIG. 7A




INF-HA-2-V2

FIG. 7B




INF-HA-2-V3

FIG. 7C




INF-HA-2-V4

FIG. 7D




INF-HB-1-V1

FIG. 8A




INF-HB-1-V2

FIG. 8B



INF-HB-1-V3

FIG. 8C



INF-HB-1-V4

FIG. 8D



H3N2 (Hong Kong/1/1968)
H3N2 (Fujian/411/2002-like)
H1N1 (New Caldonia/20/1999)
0 40 80 120 160 200 240 280 320
HI Titer (1/x)
Control
Discosites (Ribi)
Discosites (Montanide)
Discosites (Alum)
Commercial

FIG. 9



H3N2 Challenge
Percent survival
100
75
50
25
0
1
6
11
16
21
Time (days)
Control
UniFlu (Ribi)
UniFlu (Montanide)
UniFlu (Alum)
Commercial

FIG. 10



INF-01P + Montanide
INF-01P + Alum
INF-01P + Ribi
Commercial
Naïve Control
Mean Weight Loss (%)
0
10
20
30
40
50
60
70
80
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Days Post-Challenge

FIG. 11




H3N2 A/Hong Kon/1/68g
H1N1 A/FM/1/47
H5N1 A/Hong Kong/213/2003
B/Mass/3/66
H1N1 A/ New Caledonia/20/1999
Control
Commercial
INFE-01P plus Alum
0
20
40
60
80
100
120
140
160
180
HI titre (1/x)

FIG. 12



12 = Discosite & Alum
11 = Discotope construct & Ribi
10 = Discosite construct + Montanide
9 = Commercial Vaccine
8 = Unvaccinated
7 = Decreasing Concentration of Virus
6 = Blood Alone

FIG. 13



Influenza Vaccine ELISA Test
Absorbance at 490 nm
3.5
3
2.5
2
1.5
1
0.5
0
1/50
1/100
1/300
1/900
1/2700
1/8100
Antibody Titer
Discosite IFN-1+Ribi
Discosite IFN-2+Ribi
Discosite IFN-3+Ribi
Discosite IFN-4+Ribi
Discotope 1+ Ribi
Discotope 2+ Ribi
Discotope 3+ Ribi
Discotope 4+ Ribi
Control (Ribi alone)
Discosite IFN-1-4+Ribi
Discotope 1-4+ Ribi
Discosite IFN-1-4+Montanide
Commercial Vaccine

FIG. 14